藥明巨諾(02126.HK)部分行使超額配股權 多籌2.68億元
藥明巨諾(02126.HK)公布,聯席全球協調人於上週五(27日)部分行使招股章程所述的超額配股權,涉及合共1,173萬股超額配發股份,相當於根據全球發售初步可供認購的發售股份總數約12.01%。公司將按每股股份23.8元配發及發行超額配發股份。超額配發股份將用於向WuXi AppTec(Hong Kong) Holding Limited歸還為補足國際發售中股份超額分配而借入的部分股份。公司將就相關超額配發股份額外錄得2.68億元發行所得淨額。
另外全球發售的穩定價格期已於上週五結束。高盛(亞洲)作為穩定價格經辦人於穩定價格期間,於國際發售中超額配發合共1,465.35萬股股份,相當於根據全球發售初步可供認購的發售股份總數約15%;Goldman Sachs International根據借股協議向WuXi AppTec(Hong Kong) Holding Limited借入相關股份,以補足國際發售的超額分配。
其於穩定價格期以介乎每股股份19.4元至23.8元的價格在市場先後購入合共504.7萬股,並以介乎23.8元至31.35元的價格在市場出售合共212.3萬股股份。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.